Skip to main content

Table 4 Take-home medications and late clinical outcomes

From: Lower serum triglyceride level is a risk factor for in-hospital and late major adverse events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention- a cohort study

  Lower-TG group Higher-TG group P
N 157 84  
Take-home medications    
  Aspirin (%) 153 (97.5) 84 (100.0) 0.301
  Clopidogrel (%) 154 (98.1) 83 (98.8) 1.000
  *RAAS inhibitor (%) 145 (92.4) 77 (91.7) 1.000
  Beta Blocker (%) 77 (47.2) 47 (56.0) 0.375
  Statin (%) 91 (58) 54 (64.3) 0.414
  Fibrate (%) 2 (1.3) 11 (13.1) <0.001
Follow-up years (mean) 1.23 (0.22-3.78) 1.40 (0.44-3.73) 0.126
MACE    
  Non-fatal MI (%) 17 (10.8) 3 (3.6) 0.0731
  TVR (%) 34 (21.7) 8 (9.5) 0.0111
  De novo lesion (%) 9 (5.7) 4(4.8) 0.404
  Cardiac Death (%) 7 (4.5) 0 (0) 0.1688
  All-Cause Mortality (%) 13 (8.3) 1 (1.2) 0.1392
  Overall (%) 41 (26.1) 10 (11.9) 0.0137
  1. *Including angiotensin-converting-enzyme inhibitors and angiotensin-II receptor blockers. derived from Log-Rank test. MACE, major adverse cardiovascular events; MI, myocardial infarction; RAAS, rennin-angiotensin-aldosterone system; TVR, target vessel revascularization.